EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stenotrophomonas maltophilia infections: Current status on first-line therapy and other treatment options

Nisanart Charoenlap, Suleepon Poomchuchit, Skorn Mongkolsuk, Paiboon Vattanaviboon iD

Acta Microbiologica et Immunologica Hungarica · 29.05.2026 · 73 (2) · 119-130

DOI: 10.1556/030.2026.02883 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, erschienen am 29.05.2026. Verfasst von Nisanart Charoenlap und 3 weiteren Autor:innen. Beteiligte Einrichtung: 1Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 180 Literaturangaben. Gefördert von: Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stenotrophomonas maltophilia is an opportunistic pathogen primarily associated with hospital-acquired infections, particularly in individuals who are immunocompromised. S. maltophilia infections pose a significant clinical challenge due to the bacterium's sophisticated intrinsic and acquired mechanisms, which render it naturally multidrug resistant. The management of such infections is thus difficult, as the availability of effective therapeutic agents is limited. Antibiotic therapy options include co-trimoxazole, minocycline, tigecycline, levofloxacin, cefiderocol, and ceftazidime-avibactam. Co-trimoxazole, which comprises a synergistic combination of trimethoprim and sulfamethoxazole, remains the recommended first-line therapy for S. maltophilia infections. In this review, we critically evaluate the current evidence on the efficacy of co-trimoxazole against S. maltophilia . The present global prevalence of co-trimoxazole resistance in S. maltophilia clinical isolates varies from

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stenotrophomonas maltophiliaAnti-Bacterial AgentsGram-Negative Bacterial InfectionsHumansTrimethoprim, Sulfamethoxazole Drug CombinationDrug Resistance, Multiple, BacterialCefiderocol

Stichwörter der Autor:innen

SXTStenotrophomonas maltophiliaTMP-SMXantibioticantimicrobialco-trimoxazolemultidrug resistancesulfamethoxazoletrimethoprim

Substanzen

Anti-Bacterial AgentsTrimethoprim, Sulfamethoxazole Drug CombinationCefiderocol

Autor:innen und Institutionen

  • 1Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok 10210, Thailand.
  • 2Center of Excellence on Environmental Health and Toxicology (EHT), Office of the Permanent Secretary (OPS), Ministry of Higher Education, Science, Research and Innovation (MHESI), Bangkok 10400, Thailand.
  • 3Program in Applied Biological Sciences: Environmental Health, Chulabhorn Graduate Institute, Bangkok 10210, Thailand.

ORCID-Profile: Paiboon Vattanaviboon

Förderung

  • Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute

Zitieren

APA

Charoenlap, N., Poomchuchit, S., Mongkolsuk, S., & Vattanaviboon, P. (2026). Stenotrophomonas maltophilia infections: Current status on first-line therapy and other treatment options. Acta Microbiologica et Immunologica Hungarica, 73(2), 119-130. https://doi.org/10.1556/030.2026.02883

Vancouver

Charoenlap N, Poomchuchit S, Mongkolsuk S, Vattanaviboon P. Stenotrophomonas maltophilia infections: Current status on first-line therapy and other treatment options. Acta Microbiologica et Immunologica Hungarica. 2026;73(2):119-130. doi:10.1556/030.2026.02883

BibTeX
@article{Charoenlap2026,
  author = {Charoenlap, Nisanart and Poomchuchit, Suleepon and Mongkolsuk, Skorn and Vattanaviboon, Paiboon},
  title = {Stenotrophomonas maltophilia infections: Current status on first-line therapy and other treatment options},
  journal = {Acta Microbiologica et Immunologica Hungarica},
  year = {2026},
  volume = {73},
  number = {2},
  pages = {119--130},
  doi = {10.1556/030.2026.02883}
}
Kostenlos starten →